Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-04-24 |
2024-03 |
3.45 |
3.67 |
0.22 |
6.38% |
2024-02-13 |
2023-12 |
3.16 |
2.95 |
-0.21 |
-6.65% |
2023-11-08 |
2023-09 |
3.99 |
4.36 |
0.37 |
9.27% |
2023-07-25 |
2023-06 |
3.77 |
4.02 |
0.25 |
6.63% |
2023-04-25 |
2023-03 |
3.25 |
3.4 |
0.15 |
4.62% |
2023-02-15 |
2022-12 |
3.51 |
4.05 |
0.54 |
15.38% |
Date |
Firm |
Action |
From |
To |
2023-10-10 |
Morgan Stanley |
Upgrade |
Overweight |
Overweight |
2023-09-05 |
HSBC |
Upgrade |
|
Buy |
2023-09-04 |
Morgan Stanley |
Upgrade |
Overweight |
Overweight |
2023-08-28 |
RBC Capital |
Upgrade |
Outperform |
Outperform |
2023-08-13 |
Mizuho |
Upgrade |
Buy |
Buy |
2023-08-07 |
Atlantic Equities |
Upgrade |
Neutral |
Neutral |
Date |
Name |
Relation |
Quantity |
Description |
2024-02-15 |
ALEXANDER SUSAN H |
Officer |
51.68K |
Conversion of Exercise of derivative security |
2023-06-25 |
DORSA CAROLINE D |
Director |
24.82K |
Stock Award(Grant) |
2024-02-15 |
GREGORY GINGER |
Officer |
13.58K |
Conversion of Exercise of derivative security |
2023-06-25 |
HAWKINS WILLIAM A III |
Director |
5.15K |
Stock Award(Grant) |
2024-02-15 |
IZZAR RACHID |
Officer |
9.70K |
Conversion of Exercise of derivative security |
2024-02-15 |
KRAMER ROBIN C |
Officer |
6.23K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Primecap Management Company |
16.03M |
4.56B |
11.07% |
2023-06-29 |
Blackrock Inc. |
14.07M |
4.01B |
9.71% |
2023-06-29 |
Vanguard Group Inc |
12.20M |
3.47B |
8.42% |
2023-06-29 |
State Street Corporation |
6.89M |
1.96B |
4.75% |
2023-06-29 |
Wellington Management Group, LLP |
5.35M |
1.52B |
3.69% |
2023-06-29 |
JP Morgan Chase & Company |
4.47M |
1.27B |
3.09% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard/Primecap Fund |
9.00M |
2.56B |
6.21% |
2023-07-30 |
Vanguard Specialized-Health Care Fund |
4.56M |
1.23B |
3.15% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
4.51M |
1.28B |
3.11% |
2023-06-29 |
Vanguard 500 Index Fund |
3.45M |
981.68M |
2.38% |
2023-08-30 |
Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF |
2.45M |
655.85M |
1.69% |
2023-06-29 |
Vanguard Horizon Fund-Capital Opportunity Fund |
2.18M |
621.04M |
1.51% |
Split |
Date |
3 : 1 |
2001-01-18 |
2 : 1 |
1999-12-21 |